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Abstract
Background: Leishmaniasis is endemic in many countries worldwide, with a prevalence of 12 million people infected,
and an estimated annual incidence of 500 000 visceral leishmaniasis cases. In Europe visceral leishmaniasis is
considered endemic mainly in the Mediterranean countries and cases in non-endemic European countries north of
the Alps have primarily been reported in returning travellers. The incubation period is typically described between
6 weeks to 6 months. The cases presented highlight the occurrence of longer incubation periods and illustrate
the individual variability for progression from infection to disease.
Case presentation: We report the cases of 18-months-old twin girls living at the German-Swiss border, who
developed visceral leishmaniasis 7 and 15 months after travelling to Tuscany. They presented with fever of
unknown origin and pancytopenia. Both had splenomegaly and in the first case haemophagocytic lymphohistiocytosis
or leukaemia was initially included in the differential diagnosis. Diagnosis of visceral leishmaniasis was confirmed by
presence of intracytoplasmic localised leishmania parasites on bone marrow aspirate and/or positive leishmania
serology. Both girls responded well to treatment with liposomal amphotericin B. The mother and two older siblings
remained uninfected, while the father was diagnosed to be an asymptomatic carrier.
Conclusion: Visceral leishmaniasis is an important differential diagnosis for fever of unknown origin and pancytopenia
in young children living in countries with endemic disease and highlights the importance of obtaining a detailed travel
history. Hemophagocytic lymphohistiocytosis and acute leukaemia present with similar symptoms and consequently
are important differential diagnoses. Factors determining progression from infection to disease are not fully understood
but younger age seems to be an important risk factor. Screening of siblings from affected individuals therefore may be
warranted.
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Background
Leishmaniasis is endemic in at least 88 countries world-
wide, with a prevalence of 12 million people infected,
and an estimated annual incidence of 500 000 visceral
leishmaniasis cases. The World Health Organization has
estimated that the annual incidence of visceral leishman-
iasis in European countries was approximately 410 to
620 cases between 2003 and 2008 [1]. In Europe visceral
leishmaniasis is considered endemic mainly in the Medi-
terranean countries and the majority of cases are re-
ported to be from Albania, Italy and Spain.
Leishmania infantum and Leishmania donovani are
the main species causing visceral leishmaniasis with L.
infantum being the most prevalent subspecies in Europe.
Humans, rodents and canids are reservoirs and infection
follows a bite by an infected female sand fly (Phlebotomus
spp.). After inoculation of the 15–25 μm long parasite into
the tissue or blood stream it is taken up by macro-
phages which accumulate into lymphatic tissue in-
cluding spleen, liver and bone marrow. The course of
disease depends on the immune status of the host
and the specific Leishmania spp. [2].
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In the following, we are describing the cases of two
young children with visceral leishmaniasis after travelling
to Tuscany in Northern Italy. The cases presented high-
light the occurrence of longer than typically described
incubation periods and illustrate the individual variabil-
ity for progression from infection to disease in genetic-
ally related individuals. We also discuss key differential
diagnoses and the specific diagnostic and therapeutic ap-
proaches used in both cases.
Case presentation
First case
An 18-months-old twin girl was referred to our hospital
for evaluation of fever of unknown origin in January
2014. She had previously been seen by her paediatrician
for daily fever up to 40 °C for one week. Empirical treat-
ment for presumed bacterial infection with a
first-generation cephalosporin did not lead to deferves-
cence. No other symptoms including cough, vomiting,
diarrhoea, skin rash or weight loss were reported. There
were no sick contacts or exposure to pets. The girls’ previ-
ous medical history was unremarkable. She had travelled
to Tuscany for a three-week holiday six months earlier.
The girl’s twin sister, two older siblings, aged four and
six years and the parents were well at the time of her
presentation.
On physical examination, the girl’s weight and height
was 9.9 kg (10th percentile) and 84 cm (75th percentile).
She was pale and febrile (38.9 °C), without a focus of in-
fection on clinical examination. Splenomegaly noted on
clinical examination was confirmed by ultrasound with a
spleen size of 9.9 cm (normal size for age < 9 cm). Her
chest radiography was normal. Laboratory investigations
(normal values in brackets) showed: haemoglobin 75
(105–135) g/l, platelets 50 (150–450) × 109/l, white blood
cells 2.6 (6–17.5) × 109/l with 1.75% of suspected atypical
cells, C- reactive protein (CRP) 73 (< 5) mg/l and erythro-
cyte sedimentation rate (ESR) of 47 (3–13) mm/h. Liver
function tests were abnormal for aspartate aminotransfer-
ase (ASAT) 145 (26–55) U/L, alanine aminotransferase
(ALAT) 80 (9–15) U/L, lactatdehydrogenase (LDH) 1096
(< 338) U/l, and normal for gamma-glutamyltransferase
(GGT) and alkaline phosphatase (AP). Renal function tests
were normal. Serology was negative for cytomegalovirus,
parvovirus B19, Epstein-Bar virus, human herpes virus 8,
human immunodeficiency virus (HIV), hepatitis A and
toxoplasmosis. Further investigations for haemophagocy-
tic lymphohistiocytosis (HLH) showed a ferritin of 9667
(9–107) μg/l, triglycerides of 1.57 (0,7-0,8) mmol/l and
interleukin 2-receptor levels of 7950 (< 800) IU/ml. For
suspicion of leukaemia or HLH, a bone marrow aspiration
was performed which showed a normal distribution of
lymphocyte subsets with predominant T-cells but revealed
intracytoplasmic localized Leishmania parasites (Fig. 1).
Serology for leishmaniasis was strongly positive with
an antibody titre of 1:1280 (cut-off < 1:80) and was per-
formed with an in-house immunofluorescence antibody
test (IFA) using liver sections of Leishmania donovani
infected hamster. In brief, diluted serum was applied
to the sections, counter stained with a fluorescein
isothiocyanate-labeled conjugate and examined with a
fluorescence microscope. Antibodies elicited by all
members of the L. donovani complex are cross-reactive to
the L. donovani IFA. Identification and differentiation of
Leishmania spp. was performed from a bone marrow as-
pirate by polymerase chain reaction amplification of the
Miniexon with subsequent sequencing and revealed infec-
tion with Leishmania infantum [3, 4].
Treatment with liposomal amphotericin B was initi-
ated with 5 mg/kg on the first day, followed by 3 mg/kg
on each day 2–4 and 10. She received a red blood cell
transfusion on day three. The girl tolerated the treat-
ment well and her clinical condition gradually improved.
She defeveresced after the fourth treatment dose and
was discharged on day 7 with the fifth dose (day 10) ad-
ministered at the district hospital. At follow-up 1.5 years
after diagnosis the girl was well with Leishmania IFA
titre of 1:320.
Second case
Nine month later (in September 2014), the twin-sister
developed fever up to 40 °C with rhinitis. There were no
sick contacts. As her sister, she had travelled to Tuscany
for a three-weeks holiday 16 months earlier but not
returned to Tuscany afterwards or travelled to any other
country considered endemic for visceral leishmaniasis.
Laboratory investigations at the district hospital showed
a haemoglobin of 79 g/l, platelets of 60 × 109/l, white
blood cells of 4.9 × 109/l and an elevated LDH of
398 IU/l. Because of pancytopenia and the twin sisters’
previous diagnosis, the girl was referred to our hospital.
On physical examination the girl’s weight was 12.2 kg
(25th percentile) and height was 89 cm (50th percentile).
She was afebrile and presented with splenomegaly of
11.2 cm in an abdominal ultrasound. Further laboratory
investigations showed a CRP of 67 mg/l, normal liver
and renal parameters, and negative serology for HIV.
Leishmania IFA was positive with a titre of 1: 1280
(in-house L. donovani IFA as described above) and poly-
merase chain reaction amplification of the Miniexon se-
quence from blood confirmed infection with L. infantum.
Treatment with liposomal amphotericin B (5 mg/kg/d)
was started on the first day followed by 3 mg/kg/d each
on day 2–5, 10 and 21. She received a red blood cell
transfusion on day 3 because of further haemoglobin de-
cline to 67 g/l. Thrombocytes and white blood cells in-
creased on day four of admission and the girl was
discharged on day six with subsequent doses given as an
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outpatient. At the follow-up 1 year after diagnosis the
girl was thriving well and the Leishmania IFA had de-
creased to 1:320.
Evaluation of the family
Testing of the remaining asymptomatic family members
revealed a Leishmania IFA of 1:640 for the father
(in-house L. donovani IFA as described above). He
remained asymptomatic, did not receive treatment but is
regularly followed the at the outpatient clinic of the
Swiss Tropical and Public Health Institute in Basel. The
mother and the two older siblings remained asymptom-
atic with negative Leishmania IFA test results.
Discussion and conclusion
Occurrence of visceral leishmaniasis in Tuscany has
been known since many decades but recent reports sug-
gest an increased incidence in the year 2000 in Italy
compared to earlier years [5]. Factors assumed to be re-
sponsible for this increase remain incompletely under-
stood but challenges in the control of the vector and
animal reservoir may have contributed [5]. The specific
sand fly species capable to transmit Leishmania spp. are
now also widely distributed in central and northern Eur-
ope [6] potentially leading to autochthonous cases [7].
In addition to travel, the current increased migration of
refugees and asylum seekers to Europe may lead to an
increase in visceral leishmaniasis incidence as many indi-
viduals either originate from regions with high risk or
have to cross states known to be visceral leishmaniasis
endemic areas [8, 9].
Visceral leishmaniasis is rarely seen in children in cen-
tral and northern Europe and cases may primarily be in-
vestigated for other presumed diseases. Acute leukaemia
and hemophagocytic lymphohistiocytosis (HLH) are the
two most important differential diagnoses, since symp-
toms are similar including pancytopenia, hepatospleno-
megaly, lymphadenopathy, fever and elevated liver
enzymes. Findings suggestive of HLH are hypertriglyceri-
daemia, elevated ferritin and soluble interleukin 2-receptor
levels, but diagnosis may be challenging [10, 11]. Visceral
leishmaniasis may trigger HLH and should therefore be ex-
cluded before starting immunosuppressive therapy [10, 11].
The incubation period is usually described between
6 weeks to 6 months but may extend from 10 days up to
10 years [12]. Factors that determine progression from
infection to visceral leishmaniasis and the interval be-
tween infection and development of disease are not fully
understood. Interestingly, epidemiological studies from
several countries suggest that the majority of individuals
with Leishmania infection remain asymptomatic [13].
The host’s ability to raise a cell-mediated immune re-
sponse, notably the balance between Th1 and Th2 im-
mune response seems important [14]. While a Th1
immune response is associated with control of infection,
disease progression is observed together with a Th2 im-
mune response [15]. The importance of the cellular im-
mune response is further highlighted by the fact that
HIV coinfection is contributing to the rise in severe
courses of visceral leishmaniasis [12]. Innate immunity
including genetic host factors such as macrophage acti-
vation may also play a role for progression of disease [2].
Age seems to be an important additional risk factor for
progression as children below 5 years of age are world-
wide the most affected age group [12, 16]. This may ex-
plains why in the family described the two youngest
members progressed to visceral leishmaniasis whereas
the father remained asymptomatic. It is debateable,
Fig. 1 Haematoxylin and eosin stained bone marrow aspirate of the 18-months-old twin (case 1) showing extra- (a) and intracellular (b)
Leishmania amastigotes
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however - if family members under the age of 5 years
should be screened for visceral leishmaniasis. Interest-
ingly, both children had rather long incubation periods
of 7 and 15 months respectively. This is noteworthy, as
despite the girls’ being genetically closely related and in-
fected at the same point in time, the interval of occur-
rence of clinical symptoms varied substantially.
Treatment recommendations for visceral leishmaniasis
are depending on the causative Leishmania spp., geo-
graphic region, local development of resistance,
co-morbidities and immunity of the host and econom-
ical resources of the respective health care system [12].
An Albanian study in children reported meglumine anti-
moniate to be the first line treatment for children with
visceral leishmaniasis between 1995 and 2009 with cure
rates close to 100% [8]. Contrary to this, other countries
in the Mediterranean region and the United States Food
and Drug Administration (FDA) recommend liposomal
amphotericin B as first line treatment [17]. Recommen-
dations for doses, intervals and duration of treatment
vary however considerably. While the FDA recommends
a cumulative dose of 21 mg/kg liposomal amphotericin
B over 7 administrations (day 1–5, 14, 21) [17] the
WHO recommends a cumulative dose 18–21 mg/kg
over a 3–6 days period [12]. Further to this, a study in
Greece showed that even shorter regimens with a cumu-
lative dose of 20 mg/kg liposomal amphotericin B given
over 2 days had high cure rates of 98% [18]. The vari-
ability of available recommendations, the absence of a
European consensus on the treatment of visceral leish-
maniasis in children and the fact that different teams
cared for the patients likely explain the difference in
treatment regimens reported in the two cases here.
In conclusion, visceral leishmaniasis is an important dif-
ferential diagnosis in children with fever of unknown ori-
gin, pancytopenia and splenomegaly. Careful history
taking inducing travel history is key for a high index of
suspicion. Specific investigations including serology for
leishmaniasis and bone marrow aspirates are important to
confirm or rule-out the diagnosis. Longer than classically
described incubation periods may occur and a screening
of family members with the same exposure particularly for
children under 5 years of age should be considered.
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